Read our Recent Headlines

July 3 Biotech Update

This is the last note before the fourth and I wanted to spend time going into a new therapeutic space and highlight a new company (well, it is new to.

July 1 Biotech Update

I am back from vacation and ready to get back into the sector. I planned on talking about the CGPR space today but I will push that back until tomorrow.

June 18 Biotech Update

The summer is seasonally weak, especially after the EHA and ASCO- right? I am not sure of the exact catalyst for the move today but it is certainly moving the.

June 17 Biotech Update

Market doing a little better but biotechs seemed to take yesterday off despite the broader rally. The sector seems to be more positive today (there were certainly bright spots yesterday.

June 16 Biotech Update

The market is quite resilient. While we did not get a full reversal yesterday, the market came back and biotechs seemed to outperform. This morning is off to a good.

June 15 Biotech Update

It is a macro world and we are just living in it. Sunday night we should have known this was going to be a bad start to the week with.

The Reality for Mannkind

Mannkind, the maker of the inhaled insulin product Afrezza, is the 11th best performing biotech stock according to Finviz in the last month, up 62%. That performance is in line.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!